Prior CEO of Paratek Pharmaceuticals Inc, Boston, listed antibiotics biotech NASDAQ: PRTK. Obtained Qualified Infectious Disease Product (QIDP) designation (which allows for fast track review, +5 years exclusivity) from FDA under GAIN Act for 6 antibiotic resistance indications. Negotiated 10 out-licensing deals valued at $800m with companies such as Novartis, Merck & Co, Merck Serono, Bayer, Warner Chilcott and others. Led $111m financing that took Paratek public via reverse merger and $80 million in capital through various structures prior to the reverse merger. Over 20 years of experience in biopharmaceuticals in a variety or roles and companies including consulting, finance, regulatory, operations, alliance management and licensing.